Applied genetic technologies corp (AGTC)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Jun'13
ASSETS
Current assets:
Cash and cash equivalents

58,491

18,076

16,272

26,703

21,570

23,978

26,472

31,065

47,633

70,345

48,734

30,706

35,500

42,499

55,980

28,868

17,884

44,402

140,260

39,187

44,483

44,229

46,836

8,623

8,030

8,893

Investments

26,026

44,479

54,839

55,292

67,665

72,097

78,968

73,840

64,167

49,312

76,469

95,994

96,228

74,826

77,338

69,664

115,811

105,614

25,694

22,454

17,796

31,113

44,078

64,450

16,500

14,000

Milestone receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,000

-

-

-

-

-

-

-

Grants receivable

-

169

13

13

26

116

219

210

133

203

182

174

169

78

34

954

1,011

896

915

883

1,255

971

1,039

487

363

143

Prepaid and other current assets

2,942

1,993

2,054

2,276

2,948

2,959

2,527

4,009

3,968

4,012

3,228

3,361

3,797

2,574

2,510

3,089

2,071

1,890

1,929

1,608

1,575

1,121

1,156

1,876

-

475

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

690

-

Total current assets

87,459

64,717

73,178

84,284

92,209

99,150

108,186

109,124

115,901

123,872

128,613

130,235

135,694

119,977

135,862

102,575

136,777

152,802

173,798

64,132

65,109

77,434

93,109

75,436

25,583

23,511

Investments, net of current portion

-

-

-

-

-

-

-

-

0

-

4,385

11,749

16,995

41,754

33,440

74,183

46,778

40,591

33,367

23,629

29,489

21,411

10,073

-

-

-

Property and equipment, net

4,216

4,053

4,137

4,430

4,500

4,778

5,016

5,254

5,526

3,235

2,621

2,661

2,720

2,881

2,509

2,627

2,529

513

443

478

533

518

420

381

362

341

Intangible assets, net

1,176

1,127

1,062

1,013

994

954

949

968

-

-

-

1,219

1,264

1,288

1,308

1,321

1,366

1,408

1,428

1,448

1,447

1,502

1,535

1,586

1,573

1,630

Investment in Bionic Sight

8,115

-

-

1,945

-

-

-

-

1,995

2,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment in Bionic Sight

-

1,930

1,936

-

1,952

1,961

1,972

1,980

-

-

2,000

2,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right of use assets – operating leases

3,503

3,580

3,654

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right of use asset – finance lease

91

103

114

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

480

-

-

-

-

-

-

Other assets

544

6,741

544

544

1,260

1,260

1,205

1,206

2,025

2,226

1,355

59

2,107

52

99

91

-

-

-

7

7

7

38

4

1,752

8

Grants receivable and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

602

763

1,090

-

-

-

-

-

-

-

Total assets

105,104

82,251

84,625

92,216

100,915

108,103

117,328

118,532

125,447

131,333

138,974

147,923

158,780

165,952

173,218

180,797

188,052

196,077

210,126

90,174

96,585

100,872

105,175

77,407

29,270

25,490

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable

3,013

5,713

1,338

1,331

1,450

1,664

3,029

945

1,322

1,036

2,468

998

817

718

1,082

1,331

1,485

817

7,597

1,191

764

517

1,059

949

1,253

792

Accrued and other liabilities

9,434

8,513

7,185

8,024

7,024

5,823

5,677

7,155

8,035

6,116

5,423

6,162

6,372

6,167

5,845

6,514

6,068

6,122

6,313

3,451

3,028

2,207

2,179

1,585

-

-

Lease liabilities – operating

1,054

659

641

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability – finance

47

46

46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

12,701

16,319

6,295

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

8,188

11,945

14,651

20,996

-

-

-

46,898

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

921

360

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

24,818

36,033

43,725

-

46,898

46,898

46,898

-

-

-

-

-

-

212

Total current liabilities

13,548

14,931

9,210

9,355

8,474

20,188

25,025

14,395

17,545

19,097

22,542

28,156

32,007

42,918

50,652

54,743

54,451

53,837

60,808

4,642

3,792

2,724

3,238

2,534

2,174

3,460

Lease liabilities – operating, net of current portion

4,329

4,882

5,052

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability – finance, net of current portion

51

63

75

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

-

-

-

7,731

9,106

610

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

-

-

-

-

-

-

912

-

1,029

4,438

8,411

5,103

8,214

16,766

28,491

40,215

51,939

-

-

-

-

-

-

-

Other liabilities

2,357

2,336

2,315

4,152

4,139

4,209

4,258

4,345

2,294

653

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

551

110

Total liabilities

20,285

22,212

16,652

13,507

12,613

32,128

38,389

19,350

20,751

19,750

23,571

32,594

40,418

48,021

58,866

71,509

82,942

94,052

112,747

4,642

3,792

2,724

3,238

2,534

2,725

3,570

Commitments and contingencies

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

58,103

Stockholders' equity:
Preferred stock, par value $0.001 per share, 5,000 shares authorized; no shares issued and outstanding

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock, par value $0.001 per share, 150,000 shares authorized; 25,784 and 18,226 shares issued; 25,764 and 18,207 shares outstanding at March 31, 2020 and June 30, 2019, respectively

25

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

18

16

16

16

16

14

0

-

Additional paid-in capital

251,819

215,857

215,168

214,324

213,395

212,550

211,320

210,139

209,015

207,778

206,408

204,937

203,492

202,240

200,742

199,303

197,853

196,737

195,136

174,168

173,468

172,497

171,636

139,193

12,637

12,243

Shares held in treasury of 20 and 19 at March 31, 2020 and June 30, 2019, respectively

88

88

88

85

77

70

57

49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares held in treasury of: 11 and 0 at June 30, 2018 and 2017 respectively

-

-

-

-

-

-

-

-

23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated deficit

-166,937

-155,748

-147,125

-135,548

-125,034

-136,523

-132,342

-110,926

-104,314

-96,213

-91,023

-89,626

-85,148

-84,327

-86,408

-90,033

-92,761

-94,730

-97,775

-88,652

-80,691

-74,365

-69,715

-64,334

-59,813

-48,426

Total stockholders' equity

84,819

60,039

67,973

78,709

88,302

75,975

78,939

99,182

104,696

111,583

115,403

115,329

118,362

117,931

114,352

109,288

105,110

102,025

97,379

85,532

92,793

98,148

101,937

74,873

-47,176

-36,183

Total liabilities and stockholders' equity

105,104

82,251

84,625

92,216

100,915

108,103

117,328

118,532

125,447

131,333

138,974

147,923

158,780

165,952

173,218

180,797

188,052

196,077

210,126

90,174

96,585

100,872

105,175

77,407

29,270

25,490